On December 3, 2020, the Federal Trade Commission (FTC) published its annual report on pharmaceutical patent settlements filed with the FTC under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003...more
12/8/2020
/ Abbreviated New Drug Application (ANDA) ,
Biologics ,
Department of Justice (DOJ) ,
Federal Trade Commission (FTC) ,
FTC v Actavis ,
Generic Drugs ,
Life Sciences ,
Medicare Prescription Drug Improvement and Modernization Act (MMA) ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Popular ,
Prescription Drugs ,
Reverse Payment Settlement Agreements
On February 3, 2020, the Federal Trade Commission ("FTC") and the Food and Drug Administration ("FDA") issued a joint statement and plan seeking to advance biosimilar competition and combat deceptive and anticompetitive...more
2/14/2020
/ Anticompetitive Behavior ,
Antitrust Litigation ,
Antitrust Violations ,
Biologics ,
Biosimilars ,
Class Action ,
Federal Trade Commission (FTC) ,
Food and Drug Administration (FDA) ,
Joint Statements ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Popular ,
Reverse Payment Settlement Agreements ,
Unfair or Deceptive Trade Practices
On May 23, 2019, the Federal Trade Commission (FTC) published its annual report on pharmaceutical patent settlements filed with the FTC under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA),...more